Asia Pacific Antifungal Drugs Market: By Product Type (Azoles, Allylamines, Echinocandins, Polyenes and Others), By Dosage Forms (Solutions, Tablets & Capsules, Ointments & Creams, Powders, and Others), By Application (Aspergillosis, Candidiasis, Dermatophytosis, and Others) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Drug Stores), and Country  

Purchase Option

$ 3100
$ 4600
$ 6900

Asia Pacific Antifungal Drugs Market size was valued at USD 2,600.0 million in 2022 and is expected to reach USD 3,421.4 million by 2028, at a CAGR of 4% from 2023-2029.  The majority of fatal fungal infections affect people with weakened immune systems, including those affected by HIV/AIDS, cancer treatment, and hematology, among other conditions. Another significant reason boosting demand for antifungal medications is the rising prevalence of immunodeficiency disorders and invasive fungal infections. The ease of use of antifungal medicines, including oral pills, topical creams and ointments, IV drips, and over-the-counter pharmaceuticals, is another important reason driving up demand for antifungal medications in the healthcare industry. Additionally, the market is expanding as a result of increased R&D for newly developed drugs designed to treat fungal infections. 

Asia Pacific Antifungal Drugs Market Dynamics

The major factors driving the market are rising awareness of fungal infections with the increasing antifungal infections all over the world, rising government and corporate funding in the industry.

Asia Pacific Antifungal Drugs Market Segmentation

By Product Type
  • Azoles
  • Allylamines
  • Echinocandins
  • Polyenes
  • Others
By Dosage Forms
  • Solutions
  • Tablets & Capsules
  • Ointments & Creams
  • Powders
  • Others
By Application
  • Aspergillosis
  • Candidiasis
  • Dermatophytosis
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores

Frequently Asked Questions

The asia pacific antifungal drugs market size was valued at USD 2,600.0 million in 2022

The report covers the countries market data: China, India, Japan, Australia & New Zealand

Astellas Pharma, Inc. (Japan) Bayer AG (Germany) Enzon Pharmaceuticals, Inc. (U.S.) GlaxoSmithKline plc. (U.K.) Merck & Co., Inc. (U.S.) Novartis AG (Switzerland)

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Astellas Pharma, Inc. (Japan)
  • Bayer AG (Germany)
  • Enzon Pharmaceuticals, Inc. (U.S.)
  • GlaxoSmithKline plc. (U.K.)
  • Merck & Co., Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (U.S.)
  • Sanofi (France)

Adjacent Markets